Fibrobiologics Announces Preliminary Proof of Concept for Fibroblast-Based Diabetes Treatment
HOUSTON , March 19, 2024 /PRNewswire/ — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”) is focused on developing therapeutics and potential, with more than 150 patents issued and pending. is a clinical-stage biotechnology company.Treatment of chronic diseases using fibroblasts and fibroblast-derived materials announces progress on clinical program in development using insulin-secreting fibroblast-based pancreatic beta cell spheroids in vitro upon glucose stimulation. The development and reproducibility of this study demonstrates that organoids composed of fibroblasts, beta cells, and other components can secrete insulin normally and sustainably.
“This initial proof of concept is encouraging and could lead to new and durable allogeneic treatment options for patients with insulin-dependent diabetes,” said Chief Scientific Officer Dr. Hamid Khoja. “We look forward to confirming these initial results and in vivo utility. He will then decide whether to designate this program as an early-stage preclinical project to develop minimally invasive treatments for type 1 diabetes. ”
About diabetes
Diabetes mellitus is a chronic, heterogeneous metabolic disease characterized by elevated blood sugar levels due to abnormalities in insulin production or action, affecting more than 37 million people in the United States and more than 500 million people worldwide. Type 1 diabetes, an autoimmune disease in which the immune system destroys insulin-producing pancreatic beta cells, accounts for 10% of diabetes cases worldwide, with type 2 diabetes, where the body does not respond to insulin, accounting for the remainder. This accounts for 90 cases. Percentage of diabetes cases. The prevalence of this disease is so high and increasing that over 200 million people rely on consistent, often daily, insulin therapy for their health. To date, no durable, long-term, and economical treatment options are available.
Cautionary note regarding forward-looking statements
This communication contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information regarding the potential for organoids composed of fibroblasts, beta cells, and other components to successfully and sustainably secrete insulin and provide therapeutic treatments. our expectations regarding insulin-dependent diabetes and plans for current and future product candidates and programs; These forward-looking statements are based on FibroBiologics management’s current expectations, estimates, projections and beliefs and a number of assumptions regarding future events. When used in this communication, the terms “estimate,” “anticipate,” “expect,” “anticipate,” “anticipate,” “plan,” “intend,” “believe,” and “seek.” “,” “may,” “will,” “should,” “future,” “suggests,” and variations of these words or similar expressions (or such (negative versions of words and expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors; Many are beyond the control of Fibrobiologics’ management and may have actual consequences. The results described in the “Risk Factors” caption and elsewhere in FibroBiologics’ annual, quarterly, and current reports (i.e., Form 10-K, Form 10-Q, and Form 8) The results may differ materially from those discussed in the forward-looking statements, including; -K) filed or furnished to the SEC and subsequent public filings. A copy is available on the SEC website.www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) FibroBiologics’ ability to continue to meet NASDAQ listing requirements; (b) risks related to FibroBiologics’ liquidity and ability to maintain sufficient capital resources to conduct its operations; (c) our ability to effectively manage our business as a result of the majority power of attorney given to our board of directors; (d) expectations regarding the initiation, progress and expected results of our research and development efforts and preclinical studies; (e) research and development and unpredictable relationships between preclinical and clinical study results; Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements and Fibrobiologics does not warrant that any forward-looking statements, whether as a result of new information, future events or otherwise, We undertake no obligation or intention to update or revise these forward-looking statements. , or not. FibroBiologics gives no guarantee that it will achieve your expectations.
About Fibrobiologics
Houston-based FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and exploring potential treatments for chronic diseases using fibroblasts and fibroblast-derived materials. is. FibroBiologics has over 150 patents issued/pending in the U.S. and internationally across a variety of clinical pathways including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversal of organ regression, and cancer. doing. FibroBiologics represents the next generation of medical advances in cell therapy. For more information, please visit:www.FibroBiologics.com.
Public relations activities for investors:
Nick Johnson or Dr. Harrison Seidner
Russo Partners
(646) 942-5599
[email protected]
Media contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]
General inquiries:
[email protected]
Source Fibrobiologics
